Page last updated: 2024-09-03

dx 9065a and thromboplastin

dx 9065a has been researched along with thromboplastin in 12 studies

Compound Research Comparison

Studies (dx 9065a)	Trials (dx 9065a)	Recent Studies (post-2010) (dx 9065a)	Studies (thromboplastin)	Trials (thromboplastin)	Recent Studies (post-2010) (thromboplastin)
92	7	8	10,540	281	2,126

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (41.67)	18.2507
2000's	7 (58.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aoshima, K; Asakura, H; Ikeda, T; Jokaji, H; Kumabashiri, I; Matsuda, T; Morishita, E; Saito, M; Uotani, C; Yamazaki, M	2
Hara, T; Ishihara, H; Iwamoto, M; Tanabe, K; Yokoyama, A	1
Prasa, D; Stürzebecher, J; Svendsen, L	1
Avril, C; Bono, F; Herault, JP; Herbert, JM; Schaeffer, P	1
Carmeliet, P; de Prost, D; Herbert, JM; Melis, E; Ollivier, V	1
Akahane, K; Higure, A; Itoh, H; Kikuchi, M; Kitahara, K; Ohsato, K; Ohuchida, T; Okamoto, K; Takeda, S; Todoroki, H	1
Nagashima, H	1
Alexander, J; Becker, RC; Dyke, CK; Harrington, RA	1
Alexander, JH; Becker, RC; Harrington, RA; Kunitada, S; Li, Y; Robertson, T; Spencer, FA; Yang, H	1
Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N	1
Graff, J; Harder, S; Picard-Willems, B	1

Reviews

1 review(s) available for dx 9065a and thromboplastin

Article	Year
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thrombosis and haemostasis, 2004, Volume: 92, Issue:6 Topics: Animals; Anticoagulants; Area Under Curve; Blood Coagulation; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; International Normalized Ratio; Mice; Models, Biological; Models, Chemical; Naphthalenes; Pilot Projects; Platelet Aggregation Inhibitors; Propionates; Rats; Thrombin; Thromboplastin; Thrombosis; Time Factors	2004

Article

Year

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.

Thrombosis and haemostasis, 2004, Volume: 92, Issue:6

Topics: Animals; Anticoagulants; Area Under Curve; Blood Coagulation; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; International Normalized Ratio; Mice; Models, Biological; Models, Chemical; Naphthalenes; Pilot Projects; Platelet Aggregation Inhibitors; Propionates; Rats; Thrombin; Thromboplastin; Thrombosis; Time Factors

2004

Other Studies

11 other study(ies) available for dx 9065a and thromboplastin

Article	Year
Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thrombosis and haemostasis, 1994, Volume: 72, Issue:3 Topics: Administration, Oral; Animals; Anticoagulants; Disseminated Intravascular Coagulation; Drug Evaluation, Preclinical; Endotoxins; Factor Xa Inhibitors; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinogen; Kidney Glomerulus; Male; Naphthalenes; Partial Thromboplastin Time; Platelet Count; Propionates; Prothrombin Time; Rats; Rats, Wistar; Thromboplastin	1994
DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thrombosis and haemostasis, 1995, Volume: 74, Issue:2 Topics: Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Coagulation; Disseminated Intravascular Coagulation; Factor Xa Inhibitors; Fibrin Fibrinogen Degradation Products; Fibrinogen; Male; Naphthalenes; Platelet Count; Propionates; Rats; Rats, Wistar; Thromboplastin	1995
Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Seminars in thrombosis and hemostasis, 1996, Volume: 22, Issue:3 Topics: Administration, Oral; Animals; Anticoagulants; Disease Models, Animal; Disseminated Intravascular Coagulation; Factor X; Factor Xa Inhibitors; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thromboplastin	1996
Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Thrombosis and haemostasis, 1997, Volume: 78, Issue:4 Topics: Animals; Anticoagulants; Arginine; Arthropod Proteins; Cattle; Dipeptides; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hirudins; Humans; Intercellular Signaling Peptides and Proteins; Kinetics; Molecular Structure; Naphthalenes; Partial Thromboplastin Time; Peptides; Pipecolic Acids; Piperidines; Propionates; Rabbits; Recombinant Proteins; Serine Proteinase Inhibitors; Sulfonamides; Sulfones; Thrombin; Thromboplastin	1997
Activation of human vascular endothelial cells by factor Xa: effect of specific inhibitors. Biochemical pharmacology, 1999, Mar-15, Volume: 57, Issue:6 Topics: Anticoagulants; Calcium; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Naphthalenes; Oligosaccharides; Phosphatidylinositols; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Propionates; Thromboplastin	1999
Tissue factor is not involved in the mitogenic activity of factor VIIa. Biochemical and biophysical research communications, 2001, Volume: 281, Issue:5 Topics: Animals; Antithrombins; Cell Division; Cells, Cultured; Factor VIIa; Factor Xa Inhibitors; Fibroblasts; Hirudins; Mice; Mice, Transgenic; Mutation; Naphthalenes; Propionates; Thromboplastin	2001
Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery, 2001, Volume: 130, Issue:5 Topics: Animals; Chemokine CCL2; Endotoxemia; Factor Xa; Factor Xa Inhibitors; Humans; Immunohistochemistry; Lipopolysaccharides; Liver; Male; Monocytes; Naphthalenes; Propionates; Rats; Rats, Wistar; RNA, Messenger; Thromboplastin	2001
Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. The Journal of biological chemistry, 2002, Dec-27, Volume: 277, Issue:52 Topics: Anticoagulants; Arginine; Blood Coagulation; Fibrinolysis; Humans; Kinetics; Naphthalenes; Pipecolic Acids; Propionates; Sulfonamides; Thrombomodulin; Thromboplastin	2002
Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. Journal of thrombosis and thrombolysis, 2004, Volume: 18, Issue:3 Topics: Antithrombin III; Cells, Cultured; Endothelium, Vascular; Humans; Naphthalenes; Propionates; Signal Transduction; Thromboplastin	2004
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. European journal of pharmacology, 2005, May-02, Volume: 514, Issue:1 Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glycine; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombin; Thromboplastin; Thrombosis	2005
Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:4 Topics: Adult; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Daboia; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Naphthalenes; Partial Thromboplastin Time; Polysaccharides; Propionates; Thromboplastin; Viper Venoms	2007